文献速递慢性肾脏病肾小球疾病

沙库巴曲/缬沙坦通过增加肾血浆流量改善醛固酮过多2型糖尿病小鼠模型的肾小管间质损伤

Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

在8周龄雄性db/db小鼠高盐饮食基础上给予醛固酮(0.2 μg/kg/min)建立2型糖尿病伴醛固酮过多模型,分为HSD对照、ALDO、ALDO+VAL和ALDO+SAC/VAL四组,干预4周。与ALDO和ALDO+VAL组相比,ALDO+SAC/VAL组血浆ANP浓度和肌酐清除率显著升高,肾小管间质纤维化和NGAL表达显著降低;SAC/VAL还增加GFR和RPF,抑制Tgfb1、Il1b、Ccl2和Lcn2基因表达。肾小管间质纤维化面积百分比与RPF和GFR呈负相关。

要点

  • 在2型糖尿病伴醛固酮过多小鼠模型中,SAC/VAL较ALDO和ALDO+VAL显著升高血浆ANP和肌酐清除率。
  • SAC/VAL较ALDO显著增加GFR和RPF,并抑制Tgfb1、Il1b、Ccl2和Lcn2基因表达。
  • 肾小管间质纤维化面积百分比与RPF和GFR呈负相关,提示SAC/VAL获益可能经增加RPF实现。

核心结论

  • 在2型糖尿病伴醛固酮过多的小鼠模型中,SAC/VAL增加RPF和GFR并改善肾小管间质纤维化;RPF与肾小管间质损伤呈良好负相关,提示SAC/VAL的有益作用可能通过增加肾血浆流量及增强利钠肽生物利用度实现。

研究设计与样本

  • 8周龄雄性db/db小鼠喂食高盐饮食,给予溶媒或醛固酮(0.2 μg/kg/min),分为HSD对照、ALDO、ALDO+VAL和ALDO+SAC/VAL四组,干预4周后分析血浆ANP水平、肾脏组织学及血流动力学参数(FITC-菊粉测GFR,对氨基马尿酸测RPF)。

主要发现

  • 与ALDO和ALDO+VAL组相比,ALDO+SAC/VAL组血浆ANP浓度和肌酐清除率显著升高,肾小管间质纤维化和中性粒细胞明胶酶相关脂质运载蛋白表达显著降低。
  • 与ALDO组相比,SAC/VAL治疗增加GFR和RPF,并抑制Tgfb1、Il1b、Ccl2和Lcn2基因表达。
  • 肾小管间质纤维化面积百分比与RPF和GFR呈负相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aldosterone has been assumed to be one of aggravating factors in diabetic kidney disease (DKD). Natriuretic peptides/guanylyl cyclase-A/cGMP signalling has been shown to ameliorate aldosterone-induced renal injury in mice. Sacubitril/valsartan (SAC/VAL) is used clinically for chronic heart failure and hypertension, in part by augmenting natriuretic peptide bioavailability. The effects of SAC/VAL on renal pathophysiology including in DKD, however, have remained unclarified. METHODS: Eight-week-old male db/db mice fed on a high-salt diet (HSD) were treated with vehicle or aldosterone (0.2 μg/kg/min), and divided into four groups: HSD control, ALDO (aldosterone), ALDO + VAL (valsartan), and ALDO + SAC/VAL group. After 4 weeks, they were analysed for plasma atrial natriuretic peptide (ANP) levels, renal histology, and haemodynamic parameters including glomerular filtration rate (GFR) by FITC-inulin and renal plasma flow (RPF) by para-amino hippuric acid. RESULTS: The ALDO + SAC/VAL group showed significantly increased plasma ANP concentration and creatinine clearance, and decreased tubulointerstitial fibrosis and neutrophil gelatinase-associated lipocalin expression compared to ALDO and ALDO + VAL groups. SAC/VAL treatment increased GFR and RPF, and suppressed expression of Tgfb1, Il1b, Ccl2, and Lcn2 genes compared to the ALDO group. The percentage of tubulointerstitial fibrotic areas negatively correlated with the RPF and GFR. CONCLUSION: In a mouse model of type 2 diabetes with aldosterone excess, SAC/VAL increased RPF and GFR, and ameliorated tubulointerstitial fibrosis. Furthermore, RPF negatively correlated well with tubulointerstitial injury, suggesting that the beneficial effects of SAC/VAL could be through increased renal plasma flow with enhanced natriuretic peptide bioavailability.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Nishio H, Ishii A, Yamada H, et al. Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess. Nephrol Dial Transplant. 2023. PMID: 37202215. doi:10.1093/ndt/gfad098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。